Merck Mines Mevacor Switch Data To Press FDA On Self-Selection Stance
By
Dan Schiff / Email the Author / “The Tan Sheet” Jan. 9, 2012, Vol. 20, No. 02
OTCs / Word Count: 802 / Article # 05120109007
Executive Summary
Purchase decisions in OTC switch self-selection studies offer insight into subjects’ thinking “and how they might act in a real-world pharmacy setting,” Merck tells FDA in response to a draft guidance that says such decisions are driven by cost and are “an unreliable surrogate” for self-selection.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.